• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

遗传性女性癌症:管理与降低风险手术。

Hereditary Women's Cancer: Management and Risk-Reducing Surgery.

机构信息

Department of General Surgery and Medical-Surgical Specialties, Institute of Obstetrics and Gynecology, A.O.U. Policlinico Rodolico, San Marco, University of Catania, 95125 Catania, Italy.

Department of Woman and Child Health and Public Health, Catholic University of the Sacred Heart, 00168 Rome, Italy.

出版信息

Medicina (Kaunas). 2023 Feb 6;59(2):300. doi: 10.3390/medicina59020300.

DOI:10.3390/medicina59020300
PMID:36837501
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9967188/
Abstract

Hereditary women's syndromes due to inherited mutations result in an elevated risk of developing gynecological cancers over the lifetime of affected carriers. The BRCA 1 and 2 mutations, Lynch syndrome (LS), and mutations in rare hereditary syndromes increase this risk and require more effective management of these patients based on surveillance and prophylactic surgery. Patients need counseling regarding risk-reducing surgery (RRS) and the time required to perform it, considering the adverse effects of premenopausal surgery and the hormonal effect on quality of life, bone density, sexual activity, and cardiological and vascular diseases. Risk-reducing salpingo-oophorectomy (RRSO) is the gold standard for BRCA-mutated patients. An open question is that of endometrial cancer (EC) risk in patients with BRCA1/2 mutation to justify prophylactic hysterectomy during RRSO surgical procedures. RRS provides a 90-95% risk reduction for ovarian and breast cancer in women who are mutation carriers, but the role of prophylactic hysterectomy is underinvestigated in this setting of patients. In this review, we evaluate the management of the most common hereditary syndromes and the benefits of risk-reducing surgery, particularly exploring the role of prophylactic hysterectomy.

摘要

遗传性女性综合征由遗传突变引起,会增加携带者一生中患妇科癌症的风险。BRCA1 和 2 突变、林奇综合征(LS)以及罕见遗传性综合征的突变会增加这种风险,需要根据监测和预防性手术对这些患者进行更有效的管理。需要就预防性手术(RRS)和进行手术所需的时间向患者提供咨询,考虑到预防性手术对绝经前患者的不利影响以及激素对生活质量、骨密度、性行为和心血管疾病的影响。对于 BRCA 突变患者,输卵管卵巢切除术(RRSO)是金标准。一个悬而未决的问题是 BRCA1/2 突变患者的子宫内膜癌(EC)风险,这是否需要在 RRSO 手术期间预防性子宫切除术。对于携带突变的女性,RRS 可将卵巢癌和乳腺癌的风险降低 90-95%,但在这种情况下,预防性子宫切除术的作用尚未得到充分研究。在这篇综述中,我们评估了最常见遗传性综合征的管理以及预防性手术的益处,特别是探讨了预防性子宫切除术的作用。

相似文献

1
Hereditary Women's Cancer: Management and Risk-Reducing Surgery.遗传性女性癌症:管理与降低风险手术。
Medicina (Kaunas). 2023 Feb 6;59(2):300. doi: 10.3390/medicina59020300.
2
Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.预防性卵巢切除术:降低美国上皮性卵巢癌死亡率。一场持续的争论。
Oncologist. 1996;1(5):326-330.
3
Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.BRCA 突变携带者的双侧预防性乳房切除术:外科医生需要了解的内容。
Ann Ital Chir. 2019;90:1-2.
4
Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.对携带BRCA1或BRCA2基因突变的女性进行降低风险的双侧输卵管卵巢切除术。
Cochrane Database Syst Rev. 2018 Aug 24;8(8):CD012464. doi: 10.1002/14651858.CD012464.pub2.
5
Short- and long-term outcomes for single-port risk-reducing salpingo-oophorectomy with and without hysterectomy for women at risk for gynecologic cancer.单孔腹腔镜下保留生育功能的输卵管-卵巢切除术联合或不联合子宫切除术用于妇科癌症高危女性的近期和远期结局。
Int J Gynecol Cancer. 2021 Feb;31(2):215-221. doi: 10.1136/ijgc-2020-001405. Epub 2020 Sep 18.
6
Prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers: what is going on in a region of northern Italy?预防性降低风险的输卵管卵巢切除术在 BRCA 基因突变携带者中的应用:意大利北部地区的情况如何?
Maturitas. 2021 Jan;143:59-64. doi: 10.1016/j.maturitas.2020.08.011. Epub 2020 Aug 31.
7
Uptake and timing of risk-reducing salpingo-oophorectomy among patients with BRCA1 and BRCA2 mutations.BRCA1 和 BRCA2 基因突变患者的风险降低输卵管卵巢切除术的吸收和时机。
Am J Obstet Gynecol. 2021 Nov;225(5):508.e1-508.e10. doi: 10.1016/j.ajog.2021.06.070. Epub 2021 Jun 23.
8
The Role of Hormonal Replacement Therapy in BRCA Mutated Patients: Lights and Shadows.BRCA 基因突变患者中激素替代疗法的作用:利弊共存。
Int J Mol Sci. 2023 Jan 1;24(1):764. doi: 10.3390/ijms24010764.
9
Use of total abdominal hysterectomy and hormone replacement therapy in BRCA1 and BRCA2 mutation carriers undergoing risk-reducing salpingo-oophorectomy.在接受降低风险的输卵管卵巢切除术的BRCA1和BRCA2突变携带者中全腹子宫切除术和激素替代疗法的应用。
Fam Cancer. 2009;8(1):23-8. doi: 10.1007/s10689-008-9208-6. Epub 2008 Aug 29.
10
Uptake of hysterectomy and bilateral salpingo-oophorectomy in carriers of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report.携带致病性错配修复基因突变携带者中子宫切除术和双侧输卵管卵巢切除术的应用:前瞻性 Lynch 综合征数据库报告。
Eur J Cancer. 2021 May;148:124-133. doi: 10.1016/j.ejca.2021.02.022. Epub 2021 Mar 17.

引用本文的文献

1
BRCA1 and Its Vulnerable C-Terminal BRCT Domain: Structure, Function, Genetic Mutations and Links to Diagnosis and Treatment of Breast and Ovarian Cancer.BRCA1及其易损的C端BRCT结构域:结构、功能、基因突变以及与乳腺癌和卵巢癌诊断与治疗的关联
Pharmaceuticals (Basel). 2024 Mar 4;17(3):333. doi: 10.3390/ph17030333.
2
Implications of a Supernumerary Nipple Breast Cancer in a BReast CAncer Sequence Variation Carrier: A Case Report.一例携带乳腺癌序列变异的副乳乳腺癌病例报告
Mayo Clin Proc Innov Qual Outcomes. 2023 Sep 20;7(5):437-442. doi: 10.1016/j.mayocpiqo.2023.08.006. eCollection 2023 Oct.
3
CA125 Levels in BRCA mutation carriers - a retrospective single center cohort study.BRCA 基因突变携带者的 CA125 水平 - 一项回顾性单中心队列研究。
BMC Cancer. 2023 Jul 1;23(1):610. doi: 10.1186/s12885-023-11116-6.
4
Paget's Disease of the Bone and Lynch Syndrome: An Exceptional Finding.骨佩吉特病与林奇综合征:一项特殊发现。
Diagnostics (Basel). 2023 Jun 17;13(12):2101. doi: 10.3390/diagnostics13122101.

本文引用的文献

1
Germline and somatic variants in ovarian carcinoma: A next-generation sequencing (NGS) analysis.卵巢癌中的种系和体细胞变异:一项二代测序(NGS)分析
Front Oncol. 2022 Dec 1;12:1030786. doi: 10.3389/fonc.2022.1030786. eCollection 2022.
2
Ultra-minimally invasive surgery in gynecological patients: a review of the literature.妇科患者的超微创手术:文献综述。
Updates Surg. 2022 Jun;74(3):843-855. doi: 10.1007/s13304-022-01248-y. Epub 2022 Apr 2.
3
Homologous Recombination Deficiency: Concepts, Definitions, and Assays.同源重组缺陷:概念、定义和检测。
Oncologist. 2022 Mar 11;27(3):167-174. doi: 10.1093/oncolo/oyab053.
4
Implementation of Multigene Germline and Parallel Somatic Genetic Testing in Epithelial Ovarian Cancer: SIGNPOST Study.多基因种系和并行体细胞基因检测在上皮性卵巢癌中的应用:SIGNPOST研究
Cancers (Basel). 2021 Aug 27;13(17):4344. doi: 10.3390/cancers13174344.
5
Age of ovarian cancer diagnosis among BRIP1, RAD51C, and RAD51D mutation carriers identified through multi-gene panel testing.通过多基因panel 检测鉴定出 BRIP1、RAD51C 和 RAD51D 突变携带者的卵巢癌诊断年龄。
J Ovarian Res. 2021 Apr 29;14(1):61. doi: 10.1186/s13048-021-00809-w.
6
Endometrial Cancer Risk in Women With Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study.携带胚系 BRCA1 或 BRCA2 突变的女性的子宫内膜癌风险:多中心队列研究。
J Natl Cancer Inst. 2021 Sep 4;113(9):1203-1211. doi: 10.1093/jnci/djab036.
7
BRCA1/2 and Endometrial Cancer Risk: Implications for Management.BRCA1/2与子宫内膜癌风险:对治疗的启示
J Natl Cancer Inst. 2021 Sep 4;113(9):1127-1128. doi: 10.1093/jnci/djab037.
8
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.遗传/家族性高风险评估:乳腺癌、卵巢癌和胰腺癌,第 2.2021 版,NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2021 Jan 6;19(1):77-102. doi: 10.6004/jnccn.2021.0001.
9
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma.ESGO/ESTRO/ESP 子宫内膜癌管理指南。
Int J Gynecol Cancer. 2021 Jan;31(1):12-39. doi: 10.1136/ijgc-2020-002230. Epub 2020 Dec 18.
10
Endometrial Cancer in Germline BRCA Mutation Carriers: A Systematic Review and Meta-analysis.遗传性 BRCA 基因突变携带者的子宫内膜癌:系统评价和荟萃分析。
J Minim Invasive Gynecol. 2021 May;28(5):947-956. doi: 10.1016/j.jmig.2020.11.023. Epub 2020 Nov 27.